Dyron Jake Jue, MD
Endocrinology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 8 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
30 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jue’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A74895 · Current
Licensed to practise in California · since 2001 · expires 2026-12-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$103,772
Medicare paid this office $103,772 for 432 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 322 | $72,277 | $103 |
| Short return visit (20+ min) | 95 | $8,893 | $73 |
| New patient visit (60+ min) | 37 | $6,376 | $172 |
| New patient visit (45+ min) | 50 | $6,269 | $125 |
| Ultrasound scan of head and neck soft tissue | 51 | $4,744 | $93 |
See all 7 services
| Return visit (30+ min) | 322 | $72,277 | $103 |
| Short return visit (20+ min) | 95 | $8,893 | $73 |
| New patient visit (60+ min) | 37 | $6,376 | $172 |
| New patient visit (45+ min) | 50 | $6,269 | $125 |
| Ultrasound scan of head and neck soft tissue | 51 | $4,744 | $93 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 15 | $2,007 | $118 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $1,732 | $27 |
Who their Medicare patients are
432 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 10% · Women 66% · Also on Medicaid 3% · Health risk score 1.10. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 50% · Coronary heart disease 31% · Chronic kidney disease 23% · Cancer 15% · Atrial fibrillation 15% · Depression 15% · Heart failure 12% · Stroke 11% · COPD 9% · Dementia 6%.
The office billed $322,726, Medicare allowed $150,304 and paid $103,772; for 1,159 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 432 | 1,159 | 75 | 1.10 | $322,726 | $103,772 |
| 2023 | 413 | 2,575 | 75 | 1.12 | $271,202 | $124,131 |
| 2022 | 433 | 3,178 | 75 | 1.18 | $296,663 | $137,817 |
| 2021 | 431 | 2,167 | 75 | 1.26 | $292,589 | $141,264 |
| 2020 | 440 | 1,253 | 74 | 1.34 | $276,860 | $123,294 |
| 2019 | 482 | 1,502 | 75 | 1.30 | $321,483 | $148,711 |
| 2018 | 479 | 2,115 | 75 | 1.25 | $265,210 | $111,389 |
| 2017 | 485 | 1,302 | 75 | 1.27 | $288,977 | $120,127 |
| 2016 | 465 | 1,316 | 74 | 1.32 | $299,494 | $129,057 |
| 2015 | 467 | 2,609 | 73 | 1.32 | $317,427 | $140,009 |
| 2014 | 450 | 1,385 | 74 | 1.26 | $316,658 | $140,556 |
| 2013 | 447 | 1,320 | 74 | 1.30 | $287,375 | $131,050 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 318 | $89,787 | $112 |
| Short return visit (20+ min) | 100 | $9,924 | $79 |
| New patient visit (60+ min) | 43 | $7,567 | $176 |
| New patient visit (45+ min) | 41 | $5,927 | $145 |
| Ultrasound scan of head and neck soft tissue | 47 | $5,067 | $103 |
| Long return visit (40+ min) | 12 | $2,215 | $170 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $2,041 | $30 |
2022: 8 services
| Return visit (30+ min) | 343 | $96,391 | $113 |
| Short return visit (20+ min) | 98 | $10,681 | $83 |
| New patient visit (60+ min) | 46 | $8,565 | $186 |
| Ultrasound scan of head and neck soft tissue | 77 | $8,303 | $105 |
| New patient visit (45+ min) | 41 | $5,971 | $146 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 20 | $2,861 | $136 |
| Long return visit (40+ min) | 12 | $2,507 | $167 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $1,889 | $30 |
2021: 8 services
| Return visit (30+ min) | 349 | $104,596 | $116 |
| Short return visit (20+ min) | 103 | $10,752 | $86 |
| Ultrasound scan of head and neck soft tissue | 64 | $7,753 | $117 |
| New patient visit (60+ min) | 35 | $6,761 | $193 |
| New patient visit (45+ min) | 28 | $4,314 | $154 |
| Long return visit (40+ min) | 17 | $3,154 | $166 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 27 | $1,775 | $31 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 11 | $1,659 | $138 |
2020: 8 services
| Return visit (30+ min) | 346 | $85,306 | $96 |
| Ultrasound scan of head and neck soft tissue | 70 | $8,172 | $110 |
| Short return visit (20+ min) | 92 | $7,592 | $67 |
| New patient visit (60+ min) | 40 | $7,181 | $180 |
| New patient visit (45+ min) | 42 | $6,024 | $143 |
| Long return visit (40+ min) | 20 | $2,922 | $133 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 12 | $1,584 | $122 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 19 | $1,319 | $31 |
2019: 8 services
| Return visit (30+ min) | 369 | $91,795 | $101 |
| Short return visit (20+ min) | 117 | $9,151 | $68 |
| Ultrasound scan of head and neck soft tissue | 74 | $8,895 | $117 |
| New patient visit (45+ min) | 57 | $8,591 | $151 |
| New patient visit (60+ min) | 45 | $8,345 | $185 |
| Long return visit (40+ min) | 22 | $3,279 | $137 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 24 | $2,956 | $118 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 20 | $1,867 | $32 |
2018: 9 services
| Return visit (30+ min) | 343 | $74,157 | $92 |
| Short return visit (20+ min) | 138 | $10,135 | $61 |
| New patient visit (45+ min) | 67 | $9,504 | $142 |
| New patient visit (60+ min) | 40 | $7,063 | $177 |
| Ultrasound scan of head and neck soft tissue | 41 | $4,885 | $114 |
| Fine needle aspiration using imaging guidance | 17 | $2,278 | $127 |
| Ultrasonic guidance for needle placement | 17 | $829 | $49 |
| Administration of influenza virus vaccine | 17 | $437 | $26 |
| Influenza vaccine, quadrivalent derived from cell cultures | 17 | $380 | $22 |
2017: 9 services
| Return visit (30+ min) | 344 | $79,555 | $91 |
| Short return visit (20+ min) | 145 | $11,708 | $63 |
| New patient visit (45+ min) | 74 | $10,139 | $137 |
| New patient visit (60+ min) | 45 | $7,820 | $174 |
| Ultrasound scan of head and neck soft tissue | 35 | $3,956 | $107 |
| Fine needle aspiration using imaging guidance | 20 | $3,110 | $130 |
| Long return visit (40+ min) | 16 | $1,943 | $121 |
| Ultrasonic guidance for needle placement | 20 | $1,153 | $55 |
| Administration of influenza virus vaccine | 11 | $355 | $32 |
2016: 9 services
| Return visit (30+ min) | 349 | $86,988 | $97 |
| New patient visit (45+ min) | 77 | $10,858 | $141 |
| Short return visit (20+ min) | 116 | $9,814 | $65 |
| New patient visit (60+ min) | 46 | $8,140 | $177 |
| Fine needle aspiration using imaging guidance | 34 | $5,026 | $136 |
| Ultrasound scan of head and neck soft tissue | 23 | $2,687 | $117 |
| Long return visit (40+ min) | 19 | $2,507 | $132 |
| Ultrasonic guidance for needle placement | 34 | $1,961 | $58 |
| Blood glucose (sugar) test performed by hand-held instrument | 12 | $41 | $3 |
2015: 8 services
| Return visit (30+ min) | 379 | $102,349 | $97 |
| New patient visit (60+ min) | 63 | $11,384 | $181 |
| New patient visit (45+ min) | 64 | $9,397 | $147 |
| Short return visit (20+ min) | 88 | $6,855 | $66 |
| Long return visit (40+ min) | 27 | $4,033 | $130 |
| Fine needle aspiration using imaging guidance | 19 | $2,616 | $138 |
| Ultrasonic guidance for needle placement | 19 | $1,095 | $58 |
| Blood glucose (sugar) test performed by hand-held instrument | 11 | $47 | $3 |
2014: 7 services
| Return visit (30+ min) | 361 | $100,895 | $98 |
| New patient visit (45+ min) | 80 | $12,143 | $152 |
| New patient visit (60+ min) | 52 | $9,542 | $184 |
| Short return visit (20+ min) | 57 | $4,700 | $68 |
| Fine needle aspiration using imaging guidance | 27 | $4,490 | $136 |
| Long return visit (40+ min) | 21 | $3,085 | $129 |
| Ultrasonic guidance for needle placement | 27 | $2,373 | $72 |
2013: 7 services
| Return visit (30+ min) | 381 | $98,071 | $98 |
| New patient visit (45+ min) | 66 | $9,891 | $150 |
| New patient visit (60+ min) | 50 | $9,225 | $185 |
| Ultrasonic guidance for needle placement | 22 | $5,131 | $214 |
| Fine needle aspiration using imaging guidance | 22 | $3,281 | $137 |
| Short return visit (20+ min) | 36 | $2,853 | $68 |
| Blood glucose (sugar) test performed by hand-held instrument | 14 | $51 | $3 |
Drugs they prescribed that Part D paid
$1,808,113
Pharmacies billed $1,808,113 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,468) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,753 generic and 1,528 brand-name prescriptions · $1,808,113 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 232 | $374,252 | $1,613 |
| Mounjaro | 135 | $222,704 | $1,650 |
| Jardiance | 97 | $154,280 | $1,591 |
| Trulicity | 68 | $126,545 | $1,861 |
| Januvia | 50 | $67,386 | $1,348 |
See all 47 drugs
| Ozempic | 232 | $374,252 | $1,613 |
| Mounjaro | 135 | $222,704 | $1,650 |
| Jardiance | 97 | $154,280 | $1,591 |
| Trulicity | 68 | $126,545 | $1,861 |
| Januvia | 50 | $67,386 | $1,348 |
| Rybelsus | 34 | $40,542 | $1,192 |
| Farxiga | 29 | $38,752 | $1,336 |
| Humalog Kwikpen U-100 | 68 | $18,777 | $276 |
| Lantus Solostar | 119 | $16,677 | $140 |
| Basaglar Kwikpen U-100 | 50 | $15,201 | $304 |
| Synthroid | 108 | $11,874 | $110 |
| Novolog Flexpen | 29 | $10,872 | $375 |
| Toujeo Solostar | 14 | $10,018 | $716 |
| Tresiba Flextouch U-100 | 18 | $9,587 | $533 |
| Nano 2nd Gen Pen Needle | 71 | $8,304 | $117 |
| Levothyroxine | 579 | $6,703 | $12 |
| Testosterone | 14 | $4,641 | $332 |
| Repaglinide | 52 | $4,146 | $80 |
| Humulin N Kwikpen | 12 | $3,482 | $290 |
| Liothyronine | 38 | $3,189 | $84 |
| Metformin | 209 | $2,681 | $13 |
| Ultra-Fine Mini Pen Needle | 20 | $2,317 | $116 |
| Atorvastatin | 141 | $2,216 | $16 |
| Testosterone Cypionate | 21 | $2,005 | $95 |
| Lantus | 26 | $1,937 | $74 |
| Glipizide | 125 | $1,725 | $14 |
| Pioglitazone | 82 | $1,410 | $17 |
| Methimazole | 108 | $1,293 | $12 |
| Metformin Hcl Er | 120 | $1,272 | $11 |
| Ultra-Fine Short Pen Needle | 11 | $920 | $84 |
| Humulin R | 15 | $870 | $58 |
| Losartan | 50 | $807 | $16 |
| Rosuvastatin | 42 | $805 | $19 |
| Ultra-Fine Nano Pen Needle | 14 | $787 | $56 |
| Armour Thyroid | 14 | $756 | $54 |
| Ezetimibe | 18 | $574 | $32 |
| Gabapentin | 16 | $449 | $28 |
| Amlodipine Besylate | 48 | $418 | $9 |
| Cabergoline | 11 | $407 | $37 |
| Glimepiride | 30 | $384 | $13 |
| Levoxyl | 12 | $295 | $25 |
| Lisinopril | 28 | $292 | $10 |
| Alendronate | 47 | $282 | $6 |
| Calcitriol | 18 | $279 | $15 |
| Hydrochlorothiazide | 16 | $87 | $5 |
| Simvastatin | 17 | $45 | $3 |
| Fluticasone Propionate | 11 | $25 | $2 |
Year by year
| 2024 | 3,468 | 466 | 0% (0) | 44% | $1,808,113 |
| 2023 | 3,422 | 475 | None | 43% | $1,692,159 |
| 2022 | 3,269 | 445 | None | 43% | $1,248,959 |
| 2021 | 3,365 | 439 | None | 42% | $1,286,725 |
| 2020 | 3,208 | 425 | None | 44% | $1,114,889 |
| 2019 | 2,756 | 387 | None | 47% | $906,829 |
| 2018 | 2,625 | 357 | None | 46% | $788,546 |
| 2017 | 2,288 | 339 | None | 44% | $580,534 |
| 2016 | 2,224 | 321 | None | 45% | $549,546 |
| 2015 | 2,156 | 295 | None | 43% | $512,562 |
| 2014 | 2,128 | 276 | None | 46% | $459,779 |
| 2013 | 2,235 | 285 | None | 44% | $396,576 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 54 drugs
| Ozempic | 157 | $253,785 | $1,616 |
| Trulicity | 115 | $237,376 | $2,064 |
| Jardiance | 88 | $134,923 | $1,533 |
| Januvia | 62 | $93,269 | $1,504 |
| Lantus Solostar | 107 | $90,459 | $845 |
| Humalog Kwikpen U-100 | 56 | $75,540 | $1,349 |
| Mounjaro | 38 | $70,897 | $1,866 |
| Rybelsus | 31 | $60,648 | $1,956 |
| Farxiga | 36 | $56,518 | $1,570 |
| Novolog Flexpen | 44 | $54,362 | $1,235 |
| Forteo | 12 | $53,228 | $4,436 |
| Novolog | 20 | $25,551 | $1,278 |
| Levemir Flexpen | 19 | $23,543 | $1,239 |
| Humalog | 21 | $19,864 | $946 |
| Humulin N Kwikpen | 18 | $17,682 | $982 |
| Lantus | 30 | $15,560 | $519 |
| Praluent | 11 | $15,181 | $1,380 |
| Omnipod Dash Pods (Gen 4) | 14 | $15,002 | $1,072 |
| Synthroid | 111 | $12,316 | $111 |
| Basaglar Kwikpen U-100 | 34 | $11,770 | $346 |
| Levothyroxine | 579 | $9,503 | $16 |
| Metformin | 210 | $6,391 | $30 |
| Repaglinide | 58 | $5,870 | $101 |
| Testosterone | 15 | $5,326 | $355 |
| Nano 2nd Gen Pen Needle | 35 | $5,186 | $148 |
| Humulin R | 11 | $3,878 | $353 |
| Liothyronine | 33 | $3,730 | $113 |
| Testosterone Cypionate | 28 | $3,559 | $127 |
| Atorvastatin | 164 | $2,872 | $18 |
| Pioglitazone | 83 | $2,106 | $25 |
| Glipizide | 131 | $1,947 | $15 |
| Acarbose | 15 | $1,908 | $127 |
| Ultra-Fine Short Pen Needle | 15 | $1,778 | $119 |
| Metformin Hcl Er | 121 | $1,701 | $14 |
| Ultra-Fine Mini Pen Needle | 20 | $1,659 | $83 |
| Ultra-Fine Nano Pen Needle | 15 | $1,591 | $106 |
| Methimazole | 96 | $1,431 | $15 |
| Armour Thyroid | 16 | $1,366 | $85 |
| Losartan | 54 | $1,211 | $22 |
| Alendronate | 49 | $1,120 | $23 |
| Cabergoline | 11 | $1,050 | $95 |
| Ezetimibe | 15 | $977 | $65 |
| Gabapentin | 26 | $810 | $31 |
| Rosuvastatin | 40 | $752 | $19 |
| Insulin | 12 | $631 | $53 |
| Glimepiride | 28 | $528 | $19 |
| Calcitriol | 12 | $501 | $42 |
| Glipizide Er | 18 | $476 | $26 |
| Amlodipine Besylate | 33 | $372 | $11 |
| Levoxyl | 15 | $338 | $23 |
| Lisinopril | 24 | $294 | $12 |
| Hydrochlorothiazide | 19 | $162 | $9 |
| Simvastatin | 13 | $75 | $6 |
| Pravastatin | 12 | $73 | $6 |
2022: 51 drugs
| Trulicity | 149 | $273,581 | $1,836 |
| Januvia | 92 | $102,918 | $1,119 |
| Ozempic | 51 | $94,109 | $1,845 |
| Jardiance | 70 | $88,836 | $1,269 |
| Lantus Solostar | 111 | $82,762 | $746 |
| Rybelsus | 49 | $81,948 | $1,672 |
| Forteo | 16 | $61,173 | $3,823 |
| Farxiga | 39 | $53,054 | $1,360 |
| Humalog Kwikpen U-100 | 39 | $51,064 | $1,309 |
| Novolog Flexpen | 35 | $27,427 | $784 |
| Lantus | 44 | $26,467 | $602 |
| Novolog | 28 | $23,919 | $854 |
| Humalog | 16 | $15,405 | $963 |
| Levemir Flextouch | 17 | $11,931 | $702 |
| Levothyroxine | 633 | $11,543 | $18 |
| Synthroid | 117 | $10,882 | $93 |
| Basaglar Kwikpen U-100 | 22 | $8,862 | $403 |
| Metformin | 191 | $8,851 | $46 |
| Nano 2nd Gen Pen Needle | 50 | $6,148 | $123 |
| Novolin N Flexpen | 16 | $4,166 | $260 |
| Liothyronine | 44 | $3,947 | $90 |
| Humulin R | 11 | $3,816 | $347 |
| Ultra-Fine Nano Pen Needle | 26 | $2,841 | $109 |
| Atorvastatin | 175 | $2,788 | $16 |
| Repaglinide | 38 | $2,613 | $69 |
| Testosterone Cypionate | 28 | $2,288 | $82 |
| Acarbose | 23 | $2,006 | $87 |
| Ultra-Fine Mini Pen Needle | 23 | $2,006 | $87 |
| Rosuvastatin | 19 | $1,988 | $105 |
| Metformin Hcl Er | 124 | $1,934 | $16 |
| Glipizide | 150 | $1,834 | $12 |
| Methimazole | 103 | $1,377 | $13 |
| Losartan | 53 | $1,278 | $24 |
| Armour Thyroid | 14 | $1,266 | $90 |
| Pioglitazone | 48 | $1,224 | $25 |
| Cabergoline | 11 | $1,116 | $101 |
| Gabapentin | 18 | $865 | $48 |
| Ultra-Fine Short Pen Needle | 11 | $857 | $78 |
| Insulin | 14 | $736 | $53 |
| Alendronate | 42 | $528 | $13 |
| Insulin | 12 | $264 | $22 |
| Euthyrox | 16 | $228 | $14 |
| Glipizide Er | 17 | $225 | $13 |
| Pravastatin | 14 | $216 | $15 |
| Amlodipine Besylate | 39 | $213 | $5 |
| Lisinopril-Hydrochlorothiazide | 12 | $197 | $16 |
| Lisinopril | 22 | $192 | $9 |
| Levoxyl | 13 | $180 | $14 |
| Glimepiride | 18 | $174 | $10 |
| Hydrochlorothiazide | 16 | $115 | $7 |
| Simvastatin | 18 | $83 | $5 |
2021: 51 drugs
| Trulicity | 184 | $302,505 | $1,644 |
| Jardiance | 77 | $105,951 | $1,376 |
| Januvia | 93 | $98,427 | $1,058 |
| Lantus Solostar | 121 | $81,238 | $671 |
| Rybelsus | 31 | $59,455 | $1,918 |
| Humalog Kwikpen U-100 | 36 | $58,133 | $1,615 |
| Ozempic | 30 | $45,886 | $1,530 |
| Forteo | 12 | $43,652 | $3,638 |
| Novolog Flexpen | 41 | $38,712 | $944 |
| Levemir Flextouch | 19 | $32,138 | $1,691 |
| Humalog | 24 | $31,094 | $1,296 |
| Lantus | 45 | $28,631 | $636 |
| Victoza 3-Pak | 13 | $25,313 | $1,947 |
| Humalog Mix 75-25 Kwikpen | 15 | $22,596 | $1,506 |
| Farxiga | 11 | $16,839 | $1,531 |
| Basaglar Kwikpen U-100 | 38 | $14,897 | $392 |
| Levothyroxine | 641 | $14,151 | $22 |
| Novolog | 24 | $13,443 | $560 |
| Synthroid | 122 | $11,574 | $95 |
| Metformin | 180 | $7,025 | $39 |
| Ddavp | 13 | $5,759 | $443 |
| Toujeo Solostar | 13 | $4,689 | $361 |
| Liothyronine | 38 | $4,090 | $108 |
| Nano 2nd Gen Pen Needle | 36 | $3,824 | $106 |
| Ultra-Fine Nano Pen Needle | 31 | $3,779 | $122 |
| Humulin R | 12 | $3,388 | $282 |
| Repaglinide | 35 | $3,255 | $93 |
| Ultra-Fine Mini Pen Needle | 28 | $2,866 | $102 |
| Atorvastatin | 183 | $2,725 | $15 |
| Testosterone Cypionate | 27 | $2,178 | $81 |
| Metformin Hcl Er | 145 | $1,999 | $14 |
| Methimazole | 116 | $1,842 | $16 |
| Acarbose | 19 | $1,703 | $90 |
| Glipizide | 118 | $1,412 | $12 |
| Ultra-Fine Short Pen Needle | 16 | $1,272 | $79 |
| Pioglitazone | 59 | $1,115 | $19 |
| Armour Thyroid | 15 | $1,109 | $74 |
| Gabapentin | 32 | $1,017 | $32 |
| Losartan | 47 | $857 | $18 |
| Alendronate | 52 | $709 | $14 |
| Rosuvastatin | 21 | $489 | $23 |
| Insulin | 12 | $481 | $40 |
| Glimepiride | 19 | $329 | $17 |
| Simvastatin | 26 | $260 | $10 |
| Amlodipine Besylate | 29 | $187 | $6 |
| Lisinopril | 27 | $186 | $7 |
| Euthyrox | 15 | $145 | $10 |
| Pravastatin | 14 | $130 | $9 |
| Hydrochlorothiazide | 21 | $127 | $6 |
| Levoxyl | 13 | $127 | $10 |
| Atenolol | 12 | $58 | $5 |
2020: 46 drugs
| Trulicity | 200 | $307,256 | $1,536 |
| Lantus Solostar | 127 | $93,613 | $737 |
| Jardiance | 60 | $81,978 | $1,366 |
| Januvia | 79 | $74,921 | $948 |
| Humalog Kwikpen U-100 | 40 | $53,864 | $1,347 |
| Novolog Mix 70-30 Flexpen | 21 | $39,474 | $1,880 |
| Victoza 3-Pak | 28 | $37,638 | $1,344 |
| Levemir Flextouch | 21 | $32,680 | $1,556 |
| Novolog Flexpen | 42 | $29,266 | $697 |
| Lantus | 40 | $27,514 | $688 |
| Ozempic | 16 | $24,417 | $1,526 |
| Humalog Mix 75-25 Kwikpen | 15 | $20,137 | $1,342 |
| Levothyroxine | 599 | $15,080 | $25 |
| Humalog | 32 | $12,618 | $394 |
| Synthroid | 152 | $11,633 | $77 |
| Novolog | 23 | $9,766 | $425 |
| Basaglar Kwikpen U-100 | 30 | $8,915 | $297 |
| Ultra-Fine Nano Pen Needle | 63 | $7,728 | $123 |
| Cinacalcet | 12 | $7,188 | $599 |
| Toujeo Solostar | 12 | $6,672 | $556 |
| Repaglinide | 35 | $5,465 | $156 |
| Liothyronine | 31 | $3,574 | $115 |
| Humulin R | 12 | $3,532 | $294 |
| Atorvastatin | 175 | $2,980 | $17 |
| Ultra-Fine Mini Pen Needle | 33 | $2,909 | $88 |
| Acarbose | 22 | $1,874 | $85 |
| Metformin | 169 | $1,843 | $11 |
| Pioglitazone | 66 | $1,782 | $27 |
| Metformin Hcl Er | 115 | $1,742 | $15 |
| Methimazole | 109 | $1,509 | $14 |
| Testosterone Cypionate | 18 | $1,461 | $81 |
| Ultra-Fine Short Pen Needle | 17 | $1,347 | $79 |
| Glipizide | 124 | $1,306 | $11 |
| Armour Thyroid | 20 | $1,146 | $57 |
| Losartan | 49 | $837 | $17 |
| Alendronate | 57 | $703 | $12 |
| Insulin | 13 | $501 | $39 |
| Glimepiride | 26 | $462 | $18 |
| Levoxyl | 16 | $397 | $25 |
| Gabapentin | 19 | $386 | $20 |
| Amlodipine Besylate | 39 | $381 | $10 |
| Simvastatin | 37 | $351 | $9 |
| Pravastatin | 19 | $326 | $17 |
| Hydrochlorothiazide | 20 | $191 | $10 |
| Lisinopril | 24 | $143 | $6 |
| Metoprolol | 13 | $88 | $7 |
2019: 47 drugs
| Trulicity | 126 | $199,643 | $1,584 |
| Lantus Solostar | 122 | $83,898 | $688 |
| Januvia | 103 | $80,900 | $785 |
| Humalog Kwikpen U-100 | 52 | $57,463 | $1,105 |
| Jardiance | 41 | $51,094 | $1,246 |
| Humalog Mix 75-25 Kwikpen | 27 | $41,566 | $1,539 |
| Novolog Mix 70-30 Flexpen | 16 | $33,876 | $2,117 |
| Levemir Flextouch | 32 | $28,346 | $886 |
| Victoza 3-Pak | 25 | $26,280 | $1,051 |
| Humalog | 26 | $25,134 | $967 |
| Novolog | 23 | $21,737 | $945 |
| Novolog Flexpen | 36 | $20,665 | $574 |
| Levothyroxine | 509 | $13,697 | $27 |
| Novolog Mix 70-30 | 15 | $11,907 | $794 |
| Synthroid | 144 | $11,445 | $79 |
| Sensipar | 11 | $11,259 | $1,024 |
| Lantus | 21 | $9,774 | $465 |
| Basaglar Kwikpen U-100 | 34 | $9,152 | $269 |
| Ultra-Fine Nano Pen Needle | 51 | $6,449 | $126 |
| Ultra-Fine Mini Pen Needle | 35 | $3,608 | $103 |
| Liothyronine | 27 | $3,595 | $133 |
| Repaglinide | 22 | $3,590 | $163 |
| Humulin R | 14 | $3,380 | $241 |
| Atorvastatin | 145 | $2,755 | $19 |
| Metformin Hcl Er | 123 | $2,278 | $19 |
| Acarbose | 14 | $1,687 | $120 |
| Rosuvastatin | 14 | $1,578 | $113 |
| Ultra-Fine Short Pen Needle | 22 | $1,556 | $71 |
| Methimazole | 89 | $1,545 | $17 |
| Glipizide | 130 | $1,383 | $11 |
| Metformin | 110 | $1,286 | $12 |
| Testosterone Cypionate | 14 | $1,206 | $86 |
| Hydrocortisone | 15 | $1,043 | $70 |
| Armour Thyroid | 16 | $829 | $52 |
| Gabapentin | 26 | $794 | $31 |
| Losartan | 47 | $700 | $15 |
| Pioglitazone | 26 | $584 | $22 |
| Alendronate | 49 | $565 | $12 |
| Levoxyl | 14 | $527 | $38 |
| Insulin | 11 | $443 | $40 |
| Glimepiride | 18 | $404 | $22 |
| Pravastatin | 16 | $346 | $22 |
| Amlodipine Besylate | 22 | $267 | $12 |
| Hydrochlorothiazide | 21 | $221 | $11 |
| Simvastatin | 20 | $192 | $10 |
| Ramipril | 11 | $190 | $17 |
| Lisinopril | 12 | $65 | $5 |
2018: 45 drugs
| Trulicity | 99 | $123,990 | $1,252 |
| Januvia | 106 | $86,073 | $812 |
| Jardiance | 55 | $62,737 | $1,141 |
| Humalog Kwikpen U-100 | 51 | $48,948 | $960 |
| Novolog Mix 70-30 Flexpen | 32 | $42,787 | $1,337 |
| Lantus Solostar | 84 | $42,036 | $500 |
| Humalog Mix 75-25 Kwikpen | 22 | $36,946 | $1,679 |
| Novolog | 23 | $30,661 | $1,333 |
| Levemir Flextouch | 33 | $26,350 | $798 |
| Humalog | 26 | $24,106 | $927 |
| Victoza 3-Pak | 18 | $21,913 | $1,217 |
| Lantus | 33 | $16,949 | $514 |
| Novolog Flexpen | 34 | $14,606 | $430 |
| Sensipar | 11 | $13,668 | $1,243 |
| Levothyroxine | 503 | $13,335 | $27 |
| Novolog Mix 70-30 | 18 | $11,361 | $631 |
| Basaglar Kwikpen U-100 | 20 | $10,959 | $548 |
| Synthroid | 118 | $8,669 | $73 |
| Ultra-Fine Nano Pen Needle | 30 | $3,215 | $107 |
| Ultra-Fine Mini Pen Needle | 33 | $2,965 | $90 |
| Liothyronine | 19 | $2,244 | $118 |
| Repaglinide | 25 | $2,169 | $87 |
| Atorvastatin | 116 | $2,125 | $18 |
| Metformin Hcl Er | 116 | $1,830 | $16 |
| Humulin R | 12 | $1,764 | $147 |
| Acarbose | 14 | $1,326 | $95 |
| Glipizide | 132 | $1,286 | $10 |
| Metformin | 109 | $1,232 | $11 |
| Methimazole | 79 | $1,119 | $14 |
| Testosterone Cypionate | 16 | $1,112 | $69 |
| Armour Thyroid | 19 | $1,111 | $58 |
| Ultra-Fine Short Pen Needle | 17 | $969 | $57 |
| Hydrocortisone | 11 | $897 | $82 |
| Alendronate | 56 | $613 | $11 |
| Glimepiride | 19 | $433 | $23 |
| Losartan | 36 | $429 | $12 |
| Insulin | 17 | $406 | $24 |
| Gabapentin | 13 | $398 | $31 |
| Pravastatin | 15 | $383 | $26 |
| Pioglitazone | 21 | $300 | $14 |
| Amlodipine Besylate | 25 | $228 | $9 |
| Simvastatin | 27 | $164 | $6 |
| Ramipril | 11 | $161 | $15 |
| Hydrochlorothiazide | 15 | $135 | $9 |
| Lisinopril | 21 | $132 | $6 |
2017: 45 drugs
| Trulicity | 58 | $68,608 | $1,183 |
| Januvia | 73 | $58,820 | $806 |
| Lantus Solostar | 78 | $42,735 | $548 |
| Novolog Mix 70-30 Flexpen | 40 | $40,987 | $1,025 |
| Humalog Kwikpen U-100 | 44 | $36,142 | $821 |
| Androgel | 14 | $31,649 | $2,261 |
| Victoza 3-Pak | 17 | $25,471 | $1,498 |
| Levemir Flextouch | 42 | $23,957 | $570 |
| Lantus | 31 | $20,678 | $667 |
| Novolog | 29 | $18,947 | $653 |
| Humalog Mix 75-25 Kwikpen | 16 | $18,603 | $1,163 |
| Novolog Flexpen | 29 | $17,600 | $607 |
| Humalog | 24 | $12,392 | $516 |
| Levothyroxine | 427 | $11,796 | $28 |
| Invokana | 12 | $9,089 | $757 |
| Ddavp | 12 | $8,244 | $687 |
| Welchol | 12 | $7,180 | $598 |
| Synthroid | 98 | $7,041 | $72 |
| Repaglinide | 42 | $4,530 | $108 |
| Ultra-Fine Nano Pen Needle | 33 | $2,903 | $88 |
| Liothyronine | 27 | $2,472 | $92 |
| Ultra-Fine Mini Pen Needle | 29 | $2,266 | $78 |
| Metformin | 128 | $1,597 | $12 |
| Hydrocortisone | 18 | $1,508 | $84 |
| Atorvastatin | 80 | $1,392 | $17 |
| Acarbose | 21 | $1,340 | $64 |
| Glipizide | 139 | $1,253 | $9 |
| Metformin Hcl Er | 97 | $1,247 | $13 |
| Calcitriol | 11 | $1,224 | $111 |
| Methimazole | 70 | $925 | $13 |
| Armour Thyroid | 20 | $762 | $38 |
| Insulin | 20 | $715 | $36 |
| Insulin | 14 | $696 | $50 |
| Levoxyl | 14 | $640 | $46 |
| Novofine | 11 | $515 | $47 |
| Alendronate | 52 | $479 | $9 |
| Pioglitazone | 14 | $410 | $29 |
| Gabapentin | 16 | $354 | $22 |
| Pravastatin | 12 | $326 | $27 |
| Losartan | 28 | $293 | $10 |
| Glimepiride | 15 | $253 | $17 |
| Hydrochlorothiazide | 18 | $192 | $11 |
| Amlodipine Besylate | 17 | $163 | $10 |
| Lisinopril | 24 | $127 | $5 |
| Simvastatin | 18 | $101 | $6 |
2016: 40 drugs
| Januvia | 87 | $54,756 | $629 |
| Novolog Mix 70-30 Flexpen | 66 | $53,759 | $815 |
| Victoza 3-Pak | 39 | $37,468 | $961 |
| Trulicity | 34 | $33,571 | $987 |
| Lantus | 44 | $31,109 | $707 |
| Novolog Flexpen | 39 | $29,102 | $746 |
| Androgel | 12 | $27,104 | $2,259 |
| Humalog Kwikpen U-100 | 33 | $27,084 | $821 |
| Invokana | 39 | $25,746 | $660 |
| Lantus Solostar | 49 | $25,557 | $522 |
| Humalog | 28 | $22,752 | $813 |
| Levemir Flextouch | 32 | $21,189 | $662 |
| Sensipar | 17 | $20,862 | $1,227 |
| Novolin 70-30 | 14 | $10,490 | $749 |
| Levothyroxine | 352 | $8,929 | $25 |
| Humalog Mix 75-25 Kwikpen | 12 | $8,811 | $734 |
| Synthroid | 114 | $8,272 | $73 |
| Bd Ultra-Fine Pen Needle | 82 | $6,013 | $73 |
| Toujeo Solostar | 11 | $4,783 | $435 |
| Repaglinide | 35 | $4,090 | $117 |
| Novolog Mix 70-30 | 12 | $3,126 | $261 |
| Acarbose | 26 | $2,090 | $80 |
| Liothyronine | 17 | $1,906 | $112 |
| Metformin Hcl Er | 107 | $1,707 | $16 |
| Metformin | 130 | $1,332 | $10 |
| Glipizide | 138 | $1,263 | $9 |
| Hydrocortisone | 18 | $1,203 | $67 |
| Atorvastatin | 51 | $1,062 | $21 |
| Armour Thyroid | 18 | $1,059 | $59 |
| Methimazole | 60 | $767 | $13 |
| Pioglitazone | 15 | $658 | $44 |
| Alendronate | 44 | $474 | $11 |
| Insulin | 15 | $391 | $26 |
| Insulin | 12 | $358 | $30 |
| Losartan | 34 | $342 | $10 |
| Gabapentin | 20 | $238 | $12 |
| Amlodipine Besylate | 18 | $236 | $13 |
| Simvastatin | 30 | $199 | $7 |
| Hydrochlorothiazide | 19 | $160 | $8 |
| Lisinopril | 11 | $134 | $12 |
2015: 39 drugs
| Novolog Mix 70-30 Flexpen | 67 | $49,260 | $735 |
| Novolog Flexpen | 66 | $42,299 | $641 |
| Lantus Solostar | 66 | $39,581 | $600 |
| Januvia | 61 | $37,949 | $622 |
| Victoza 3-Pak | 39 | $28,957 | $742 |
| Humalog Kwikpen U-100 | 41 | $27,880 | $680 |
| Sensipar | 17 | $26,320 | $1,548 |
| Invokana | 37 | $26,146 | $707 |
| Lantus | 40 | $25,143 | $629 |
| Androgel | 13 | $19,606 | $1,508 |
| Levemir Flextouch | 27 | $17,112 | $634 |
| Victoza 2-Pak | 24 | $14,217 | $592 |
| Humalog | 14 | $11,541 | $824 |
| Novolin 70-30 | 13 | $9,556 | $735 |
| Levothyroxine | 323 | $8,883 | $28 |
| Bd Ultra-Fine Pen Needle | 123 | $8,150 | $66 |
| Synthroid | 96 | $5,693 | $59 |
| Novolog | 15 | $4,886 | $326 |
| Repaglinide | 23 | $4,463 | $194 |
| Novolog Mix 70-30 | 13 | $3,364 | $259 |
| Liothyronine | 22 | $2,280 | $104 |
| Acarbose | 22 | $1,861 | $85 |
| Calcitriol | 18 | $1,776 | $99 |
| Metformin | 133 | $1,534 | $12 |
| Metformin Hcl Er | 88 | $1,316 | $15 |
| Glipizide | 132 | $1,113 | $8 |
| Atorvastatin | 43 | $1,041 | $24 |
| Methimazole | 73 | $1,021 | $14 |
| Armour Thyroid | 21 | $775 | $37 |
| Insulin | 13 | $639 | $49 |
| Insulin | 18 | $571 | $32 |
| Alendronate | 53 | $494 | $9 |
| Insulin | 11 | $446 | $41 |
| Simvastatin | 45 | $393 | $9 |
| Losartan | 24 | $354 | $15 |
| Amlodipine Besylate | 18 | $225 | $12 |
| Gabapentin | 12 | $220 | $18 |
| Glimepiride | 14 | $179 | $13 |
| Hydrochlorothiazide | 17 | $134 | $8 |
2014: 42 drugs
| Novolog Mix 70-30 Flexpen | 80 | $48,365 | $605 |
| Forteo | 11 | $44,358 | $4,033 |
| Victoza 3-Pak | 47 | $37,453 | $797 |
| Januvia | 58 | $36,615 | $631 |
| Lantus Solostar | 74 | $35,242 | $476 |
| Humalog | 66 | $33,017 | $500 |
| Lantus | 59 | $27,124 | $460 |
| Novolog Flexpen | 32 | $22,372 | $699 |
| Sensipar | 23 | $17,751 | $772 |
| Novolin 70-30 | 20 | $12,376 | $619 |
| Invokana | 17 | $11,835 | $696 |
| Victoza 2-Pak | 22 | $10,624 | $483 |
| Androgel | 12 | $10,095 | $841 |
| Bd Ultra-Fine Pen Needle | 173 | $8,565 | $50 |
| Novolog | 21 | $7,596 | $362 |
| Levothyroxine | 307 | $6,901 | $22 |
| Humalog Mix 75-25 | 16 | $6,199 | $387 |
| Synthroid | 96 | $5,795 | $60 |
| Calcitriol | 14 | $3,417 | $244 |
| Novolog Mix 70-30 | 11 | $3,210 | $292 |
| Metformin | 152 | $2,087 | $14 |
| Tirosint | 12 | $1,868 | $156 |
| Acarbose | 21 | $1,291 | $61 |
| Pioglitazone | 13 | $1,271 | $98 |
| Glipizide | 114 | $1,177 | $10 |
| Metformin Hcl Er | 61 | $1,125 | $18 |
| Methimazole | 61 | $843 | $14 |
| Atorvastatin | 33 | $827 | $25 |
| Insulin | 17 | $812 | $48 |
| Cytomel | 11 | $784 | $71 |
| Hydrocortisone | 14 | $694 | $50 |
| Alendronate | 51 | $552 | $11 |
| Pravastatin | 18 | $451 | $25 |
| Glimepiride | 20 | $430 | $22 |
| Novofine | 12 | $425 | $35 |
| Novofine 32 | 13 | $421 | $32 |
| Glyburide | 18 | $420 | $23 |
| Insulin | 15 | $396 | $26 |
| Simvastatin | 33 | $368 | $11 |
| Amlodipine Besylate | 32 | $297 | $9 |
| Losartan | 17 | $286 | $17 |
| Hydrochlorothiazide | 21 | $144 | $7 |
2013: 42 drugs
| Forteo | 22 | $51,865 | $2,358 |
| Januvia | 92 | $42,420 | $461 |
| Novolog Mix 70-30 Flexpen | 71 | $36,587 | $515 |
| Lantus Solostar | 72 | $31,718 | $441 |
| Lantus | 66 | $27,087 | $410 |
| Humalog | 50 | $26,259 | $525 |
| Novolog Flexpen | 43 | $24,905 | $579 |
| Victoza 3-Pak | 31 | $20,444 | $659 |
| Sensipar | 17 | $10,386 | $611 |
| Androgel | 15 | $8,064 | $538 |
| Novolin 70-30 | 14 | $7,563 | $540 |
| Bd Ultra-Fine Pen Needle | 137 | $7,474 | $55 |
| Byetta | 11 | $5,689 | $517 |
| Humulin 70-30 | 12 | $5,408 | $451 |
| Synthroid | 111 | $5,138 | $46 |
| Victoza 2-Pak | 14 | $4,650 | $332 |
| Humalog Mix 75-25 | 18 | $4,302 | $239 |
| Novolog Mix 70-30 | 12 | $4,187 | $349 |
| Levothyroxine | 249 | $3,790 | $15 |
| Pioglitazone | 16 | $3,148 | $197 |
| Metformin | 174 | $2,880 | $17 |
| Calcitriol | 25 | $2,328 | $93 |
| Acarbose | 25 | $1,440 | $58 |
| Glipizide | 132 | $1,396 | $11 |
| Methimazole | 74 | $1,254 | $17 |
| Metformin Hcl Er | 61 | $1,254 | $21 |
| Atorvastatin | 29 | $1,253 | $43 |
| Testosterone Cypionate | 17 | $1,170 | $69 |
| Clonidine | 11 | $1,166 | $106 |
| Alendronate | 67 | $1,041 | $16 |
| Insulin | 24 | $797 | $33 |
| Insulin | 18 | $765 | $42 |
| Glimepiride | 40 | $705 | $18 |
| Glipizide Er | 15 | $652 | $43 |
| Pravastatin | 33 | $646 | $20 |
| Amlodipine Besylate | 52 | $508 | $10 |
| Insulin | 17 | $398 | $23 |
| Simvastatin | 31 | $315 | $10 |
| Losartan | 16 | $304 | $19 |
| Armour Thyroid | 18 | $200 | $11 |
| Hydrochlorothiazide | 16 | $136 | $8 |
| Lisinopril | 11 | $98 | $9 |
Money from drug and device companies
$15 in 2025
| 2025 | 1 | 1 | None | $15 |
| 2024 | 1 | 3 | None | $61 |
| 2022 | 1 | 1 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $15 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-03-12 | Tepezza | $15 |
See earlier years (2024, 2022)
2024: $61
| Amgen | Tepezza | $61 | 3 payments
|
2022: $24
| Abbott Laboratories | Freestyle Libre 2 | $24 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 13.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760484240
- Licence
- CA A74895California A74895: Current · expires 2026-12-31
- Trained
- University of California, San Diego School of Medicine, 1999
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A748950
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 2101 Forest Ave, Ste 100, San Jose, CA, 95128
- NPI first listed
- 2005-08-13
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.